Skip to main content

Advertisement

SpringerLink
Log in

Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of this study was to determine if there was a long-term increase in glycopeptide minimum inhibitory concentration (MIC) values, MIC creep, among bloodstream isolates of Staphylococcus epidermidis and S. haemolyticus isolated from patients with hematological malignancies. We conducted a retrospective single-center study where all positive blood cultures of S. epidermidis (n = 387) and S. haemolyticus (n = 19) isolated from patients with hematological malignancies during three decades, 1980 to 2009, were re-evaluated for the presence of reduced susceptibility to vancomycin and teicoplanin. Three different methods for the detection of reduced susceptibility to glycopeptides were used; standard Etest, macromethod Etest, and glycopeptide resistance detection (GRD) Etest. The median MIC value for vancomycin was 2 mg/L. MIC values for vancomycin and teicoplanin did not show any statistically significant increase during the study period. The presence of heterogeneously glycopeptide-intermediate staphylococci (hGIS) was analyzed among 405 coagulase-negative staphylococci (CoNS) isolates. hGIS were found in 31–45% of the CoNS isolates by the macromethod Etest and in 53–67% by the GRD Etest during the three decades. In conclusion, we did not observe any long-term glycopeptide MIC creep determined by the standard Etest, although a high and increasing proportion of heterogeneous vancomycin resistance was observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rogers KL, Fey PD, Rupp ME (2009) Coagulase-negative staphylococcal infections. Infect Dis Clin North Am 23(1):73–98

    Article  PubMed  Google Scholar 

  2. Wilson AP, O’Hare MD, Felmingham D, Grüneberg RN (1986) Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 2(8513):973

    Article  PubMed  CAS  Google Scholar 

  3. Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316(15):927–931

    Article  PubMed  CAS  Google Scholar 

  4. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A; The Linezolid Study Group (2000) Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 46(6):931–940

    Article  PubMed  CAS  Google Scholar 

  5. Santos Sanches I, Mato R, de Lencastre H, Tomasz A (2000) Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 6(3):199–211

    Article  PubMed  CAS  Google Scholar 

  6. de Neeling AJ, van Leeuwen WJ, Schouls LM, Schot CS, van Veen-Rutgers A, Beunders AJ, Buiting AG, Hol C, Ligtvoet EE, Petit PL, Sabbe LJ, van Griethuysen AJ, van Embden JD (1998) Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989–1995. J Antimicrob Chemother 41(1):93–101

    Article  PubMed  Google Scholar 

  7. Felmingham D, Brown DF, Soussy CJ; European Glycopeptide Resistance Survey Study Group (1998) European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. Diagn Microbiol Infect Dis 31(4):563–571

    Article  PubMed  CAS  Google Scholar 

  8. Froggatt JW, Johnston JL, Galetto DW, Archer GL (1989) Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 33(4):460–466

    PubMed  CAS  Google Scholar 

  9. Goldstein FW, Coutrot A, Sieffer A, Acar JF (1990) Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 34(5):899–900

    PubMed  CAS  Google Scholar 

  10. Grüneberg RN, Hryniewicz W (1998) Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Int J Antimicrob Agents 10(4):271–277

    Article  PubMed  Google Scholar 

  11. Herwaldt L, Boyken L, Pfaller M (1991) In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 10(12):1007–1012

    Article  PubMed  CAS  Google Scholar 

  12. Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW (2000) Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 44(12):3374–3380

    Article  PubMed  CAS  Google Scholar 

  13. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350(9092):1670–1673

    Article  PubMed  CAS  Google Scholar 

  14. Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340(7):517–523

    Article  PubMed  CAS  Google Scholar 

  15. Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE (2000) Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother 44(11):3122–3126

    Article  PubMed  CAS  Google Scholar 

  16. Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A (1998) Recurrent peritonitis in a patient on dialysis and prophylactic vancomycin. Lancet 351(9106):880–881

    Article  PubMed  CAS  Google Scholar 

  17. Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A (1999) Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 37(1):39–44

    PubMed  CAS  Google Scholar 

  18. Van Der Zwet WC, Debets-Ossenkopp YJ, Reinders E, Kapi M, Savelkoul PH, Van Elburg RM, Hiramatsu K, Vandenbroucke-Grauls CM (2002) Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit. J Clin Microbiol 40(7):2520–2525

    Article  Google Scholar 

  19. Gould IM (2008) Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31(Suppl 2):1–9

    Article  PubMed  CAS  Google Scholar 

  20. Bertin M, Muller A, Bertrand X, Cornette C, Thouverez M, Talon D (2004) Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 23(5):375–379

    Article  PubMed  CAS  Google Scholar 

  21. Boisson K, Thouverez M, Talon D, Bertrand X (2002) Characterisation of coagulase-negative staphylococci isolated from blood infections: incidence, susceptibility to glycopeptides, and molecular epidemiology. Eur J Clin Microbiol Infect Dis 21(9):660–665

    Article  PubMed  CAS  Google Scholar 

  22. Tacconelli E, Tumbarello M, Donati KG, Bettio M, Spanu T, Leone F, Sechi LA, Zanetti S, Fadda G, Cauda R (2001) Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case–control study. Clin Infect Dis 33(10):1628–1635

    Article  PubMed  CAS  Google Scholar 

  23. Biavasco F, Vignaroli C, Varaldo PE (2000) Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 19(6):403–417

    Article  PubMed  CAS  Google Scholar 

  24. Hiramatsu K, Hanaki H (1998) Glycopeptide resistance in staphylococci. Curr Opin Infect Dis 11(6):653–658

    Article  PubMed  CAS  Google Scholar 

  25. Cherif H, Kronvall G, Björkholm M, Kalin M (2003) Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4(6):420–426

    Article  PubMed  Google Scholar 

  26. Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39(7):2439–2444

    Article  PubMed  CAS  Google Scholar 

  27. Leonard SN, Rossi KL, Newton KL, Rybak MJ (2009) Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 63(3):489–492

    Article  PubMed  CAS  Google Scholar 

  28. Maniati M, Petinaki E, Kontos, Maniatis AN, Spiliopoulou I, Petropoulou-Mylona D, Malamou-Lada H, Spaliara L, Koutsia-Carouzou C (2005) Rapid increase in numbers of Staphylococcus epidermidis strains with reduced susceptibility to teicoplanin in Greece. Int J Antimicrob Agents 25(4):346–348

    Article  PubMed  CAS  Google Scholar 

  29. Trueba F, Garrabe E, Hadef R, Fabre R, Cavallo JD, Tsvetkova K, Chesneau O (2006) High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol 44(5):1922–1923

    Article  PubMed  CAS  Google Scholar 

  30. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46(2):193–200

    Article  PubMed  CAS  Google Scholar 

  31. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52(9):3315–3320

    Article  PubMed  CAS  Google Scholar 

  32. Srinivasan A, Dick JD, Perl TM (2002) Vancomycin resistance in staphylococci. Clin Microbiol Rev 15(3):430–438

    Article  PubMed  CAS  Google Scholar 

  33. Cremniter J, Slassi A, Quincampoix JC, Sivadon-Tardy V, Bauer T, Porcher R, Lortat-Jacob A, Piriou P, Judet T, Herrmann JL, Gaillard JL, Rottman M (2010) Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol 48(4):1428–1431

    Article  PubMed  Google Scholar 

  34. Natoli S, Fontana C, Favaro M, Bergamini A, Testore GP, Minelli S, Bossa MC, Casapulla M, Broglio G, Beltrame A, Cudillo L, Cerretti R, Leonardis F (2009) Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. BMC Infect Dis 9:83

    Article  PubMed  Google Scholar 

  35. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29(11):1275–1279

    Article  PubMed  CAS  Google Scholar 

  36. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by grants from the research committee of Örebro County Council, Sweden.

Transparency declarations

B. Söderquist has been a consultant for Pfizer and Janssen-Cilag.

Funding

Research Committee of Örebro County Council, Sweden.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology, Örebro University Hospital, 701 85, Örebro, Sweden

    E. Ahlstrand & U. Tidefelt

  2. Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, 701 85, Örebro, Sweden

    K. Svensson & B. Söderquist

  3. Department of Infectious Diseases, Örebro University Hospital, 701 85, Örebro, Sweden

    L. Persson & B. Söderquist

  4. School of Health and Medical Sciences, Örebro University, 701 82, Örebro, Sweden

    E. Ahlstrand, U. Tidefelt & B. Söderquist

Authors
  1. E. Ahlstrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Persson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Tidefelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Söderquist
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Ahlstrand.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahlstrand, E., Svensson, K., Persson, L. et al. Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. Eur J Clin Microbiol Infect Dis 30, 1349–1354 (2011). https://doi.org/10.1007/s10096-011-1228-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1228-8

Keywords

Search

Navigation